抗DNA酶B与ASO联合测定对小儿链球菌感染的诊断价值

目的:探讨抗DNA酶B与抗链球菌溶血素"O"(ASO)联合测定对小儿链球菌感染的诊断价值.方法:分别测定126例小儿链球菌感染患者(分成4组)和50例健康人群抗DNA酶B和ASO水平,计算各组别的阳性率,并进行分析.结果:急性不典型风湿热组、肾炎上感组、急性咽炎组等组别,抗DNA酶B与ASO联合测定阳性率差异无显著性(P>0.05).而肾炎皮损组、肾炎恢复期组差异有极显著性(P<0.01).结论:抗DNA酶B与ASO联合检测可以提高小儿链球菌感染的检出率.     

Combination of intramuscular transplantation of autologous mononuclear bone marrow cells with sympathectomy (L2, 3) in patients with peripheral arterial disease(PAD)

BackgroundIn most patients with severe, chronic extremity ischemic diseases, intervention or surgical treatment is often not suitable. Combination of intramuscular transplantation of autologous monocular bone marrow cells (AMBMCs) and sympathectomy (L2, 3) has been proved therapeutically beneficial.MethodsWe studied 170 patients (combined group 80, control group 90) with extremity ischemia (TAO, ASO FontaineⅡ,Ⅲ, Ⅳ) between January 2013 and September 2019.ResultsIn contrast to pre-operation, the walking distance of patients increased significantly (from 61.34 ± 52.23 m to 156.0 ± 32.4 m, p < 0.01), and the ankle-brachial index (ABI) remarkably improved (from 0.28 ± 0.13 to 0.59 ± 0.23, p < 0.05).ConclusionCombined therapy is feasible and effective for patients with peripheral arterial disease (PAD).     

抗链球菌溶血素O及类风湿因子定量测定

目的建立胶乳增强免疫比浊法在全自动生化分析仪上定量测定血清中抗链球菌溶血素O(ASO)、类风湿因子(RF)的方法。方法用胶乳增强免疫比浊法定量测定ASO、RF,并对其重复性、准确性、线性范围、试剂稳定性加以评价。结果二种浓度ASO、RF批内CV分别为1.96%,1.06%和2.08%,1.19%;批间CV分别为3.83%,2.89%和3.18%,2.04%;线性范围分别为65U/L~520U/L,25U/L~200U/L;平均回收率分别为99.7%和101.5%;试剂在仪器2℃~8℃的条件下放置至少可用20d。结论本次实验较好的把胶乳增强免疫比浊法和全自动生化分析仪结合在一起,定量测定血清中ASO、RF的含量,特异性强、重复性好、检测灵敏度高、线性范围宽、自动化程度高、操作简便快速。     

A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug

The combined influence of doxorubicin (DOX) and liposomal antisense oligonucleotides (ASOs) targeted to hypoxia-inducible factor 1 alpha (HIF1A) subunit on the apoptosis signaling pathways and cellular pump and nonpump resistance were investigated. Drug-sensitive A2780 and multidrug-resistant A2780/AD human ovarian carcinoma cells were used. Cells were incubated within 48h in normoxic (21% O(2), 5% CO(2) and 74% N(2)) or hypoxic (1% O(2), 5% CO(2) and 94% N(2)) conditions, with or without DOX in the concentration corresponding to the IC(50) dose, with or without liposomal ASO targeted to HIF1A mRNA. Apoptosis induction, lactic acid concentration, expression of genes and proteins involved in apoptosis signaling pathways, pump and nonpump cellular resistance were assessed. The results showed that overexpression of HIF1A protein induced by exposure to hypoxia and DOX activated both apoptotic cellular signal and cellular antiapoptotic defense. In addition, while hypoxia suppressed cellular pump resistance, due to multidrug resistance-associated protein family transporters, DOX activated pump resistance. A decrease in the expression of targeted protein (HIF1A) by liposomal HIF1A ASO effectively suppressed pump and nonpump cellular resistance and significantly enhanced apoptosis induction by hypoxia and DOX. Data obtained showed that ASO targeted to HIF1A mRNA that suppress cellular antihypoxic defense might be used as a powerful tool to improve the anticancer action of cytotoxic drug or even as an anticancer agent.     

Rapid detection of exon 1 NRAS gene mutations using universal heteroduplex generator technology

Specific NRAS oncogene missense mutations have been frequently found in some tumors and several hematological diseases, especially in those of myeloid origin. There is a wide range of PCR-based methods for screening and detection of NRAS exon 1 single-base substitutions. However, there are disadvantages and ambiguities associated with these techniques because all of them require either separate probes, separate PCR amplifications, or complicated post-PCR manipulations. This report describes a new approach for detection of NRAS gene mutations at codon 12 and 13 based on the DNA heteroduplex analysis method. The strategy relies upon differential electrophoretic behavior of induced heteroduplex molecules formed by cross-hybridization of two PCR-amplified species, the sample under analysis and the synthetic universal heteroduplex generator (UHG). The screening of a panel of all codon 12 and 13 NRAS mutant DNA variants indicated that this approach discriminates all 12 relevant mutations. The sensitivity of the method was estimated by a competitive assay where mutant alleles could be detected at a dilution level of 1 to 16 wild-type alleles. This UHG technology was tested on some clinical samples previously studied by PCR-ASO. This methodology is highly specific, sensitive, and achieves an appreciable reduction in workload and time because it requires one PCR amplification followed by polyacrylamide gel electrophoresis in standard conditions. We propose that this new approach may be applied as an alternative strategy for codon 12-13 NRAS mutations and it could be easily incorporated into the range of routine assays performed in oncology laboratories.     

基于熵的复杂系统分划方法在动脉硬化闭塞症中医证候量化诊断标准研究中的应用

目的:建立动脉硬化闭塞症(Ⅰ、Ⅱ期)中医证候量化诊断标准(包括量化诊断标准和程度分级标准)。方法:根据文献调研、专家咨询、临床流行病学调查获得动脉硬化闭塞症(Ⅰ、Ⅱ期)的四诊资料,以基于熵的复杂系统分划方法筛选症状,确定症状对证候的贡献分值,以ROC曲线分析确定证候诊断阈值。结果:建立了动脉硬化闭塞症(Ⅰ、Ⅱ期)的量化诊断标准,并对量化诊断标准进行检验,具有良好的灵敏度和特异度,最后建立了程度分级标准。结论:基于熵的复杂系统分划方法可以用于中医证候的量化诊断研究,具有较好的诊断效能。     

下肢动脉硬化性闭塞症的超声诊断分析(附89例报告)

目的:探讨双功能彩色多普勒超声在诊断下肢动脉硬化症中的应用价值。方法:回顾性地分析了89例下肢动脉硬化性栓塞病例的二维超声图像及彩色多普勒血流显像改变。结果:二维超声图像上表现为病变血管内中膜呈不规则增厚,局部呈强回声斑显示,并向血管腔内突起,血管腔内径呈不规则狭窄,病变段血管腔内可见实性光团充填,彩色多普勒血流显像显示血管腔内未见血流信号显示。结论:双功能超声对下肢动脉硬化闭塞症的诊断具有很高的灵敏性和准确性。     

Molecular analysis of β‐thalassaemia patients in a high incidence area of southern Italy

The prevalence of eight mutations in 84 patients with β‐thalassaemia major and in 16 subjects with thalassaemia intermedia was investigated. All of the patients were Italian, originating from Eastern Sicily (Messina area) and some Calabrian regions. Genomic DNA was amplified by polymerase chain reaction (PCR). DNA molecular investigations were performed by allele‐specific oligonucleotide (ASO) hybridization, to identify the following β‐thalassaemia mutations: CD39 (C‐T), IVS1‐110 (G‐A), IVS1‐6 (T‐C), IVS1‐1 (G‐A), IVS2‐745 (C‐G), IVS2‐1 (G‐A), ?87 (C‐G), CD6 A (?A). Our data underline that in thalassemia intermedia two mutations were statistically prevalent: IVS1‐6 T→C (P < 0.001) and CD 6‐A (P < 0.05). CD 39 was statistically prevalent in β‐thalassaemia major patients (P < 0.01). The difference between the two groups was not statistically significant for all the other mutations. Five different genotypes were recorded among thalassaemia intermedia and 15 among β‐thalassaemia major patients. Twenty‐five percent of the intermedia patients and 4.5% of the major patients had homozygosity for mild mutations (group I); 62.5% of the intermedia patients and 26.2% of the major patients had combinations of mild/severe mutations (group II). In addition, homozygosity or double heterozygosity for severe mutations (group III) was found in 12.5% of the intermedia patients and 69% of the major patients. Some genotypes were restricted to thalassaemia intermedia, including heterozygosity ?87/IVS1‐6 and IVS1‐6/CD 6‐A. It is essential to understand the distribution and frequency of the relevant mutations in each population where β‐thalassaemias exist. This is of particular importance for genotype–phenotype correlation and for carrier detection, genetic counselling and prenatal diagnosis.